Back to the peptide atlas
Immune researchPeptideNot FDA/EMA approved

LL-37

Antimicrobial host defence

Also known as: LL37 · Human cathelicidin

No account · this device only

The essentials at a glance

Classification
Peptide · Immune research
Mechanism
Endogenous antimicrobial host-defence peptide
Evidence
Preclinical
Status
Not FDA/EMA approved

Part of innate immunity; antimicrobial, inflammatory and wound-repair signalling are under study.

Distinction: LL-37 belongs to innate immune defence, distinguishing it from adaptively acting immune peptides such as thymosin alpha-1.

Evidence strengthPreclinical

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

Not FDA/EMA approved: No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

Research questions

Mechanism: LL-37

01

Antimicrobial host defence

Researchers study how a naturally occurring defence peptide attacks bacteria and affects inflammation signals, similar to a first line of defence for skin and mucous membranes. Bacterial growth and immune markers are measured in the lab.

02

Immune-modulating peptide

This studies how a peptide adjusts immune cell activity, similar to a dial that strengthens or dampens the immune response. Immune cell counts and inflammation markers are measured in studies.

03

Cell migration peptide

This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.

Simple example

Endogenous repair signal

Think of it like an internal alarm signal that prompts the body toward existing repair processes, similar to a call placed to the body's own repair crew.

Triggering a signal does not automatically mean a predictable or sufficient repair response across the whole organism.

Community themes

How communities discuss it

Personal experience reports and vendor marketing from communities are not scientific proof of efficacy.

Gut health anecdotes

People report subjectively perceived digestive improvements after using gastric-protective or immune-modulating peptides, usually without objective diagnostics. Such self-observations do not establish a confirmed effect on the gut.

Wound healing anecdotes

People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Evidence boundary

Antimicrobial and inflammatory effects remain under study, without a confirmed clinical use.

No peptide sales or individual recommendations. A separately labelled community area documents third-party protocol claims without medically endorsing them.